FindTrial
Sign In

trial evaluating the efficacy of omalizumab (Xolair ®) in idiopathic refractory severe solar urticaria

Therapeutic multicentric phase II trial evaluating the efficacy of omalizumab (Xolair ®) in idiopathic refractory severe solar urticaria

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2013-004910-16-FR
Enrollment
Unknown
Registered
2015-06-22
Start date
2014-03-31
Completion date
Unknown
Last updated
2015-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Trade Name: XOLAIR Product Name: XOLAIR Pharmaceutical Form: Solution and suspension for suspension for injection in pre-filled syringe

Sponsors

Centre Hospitalier régional Universitaire de Besançon
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 10 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

France

Contacts

Public ContactStéphanie FRANCOIS

Centre Hospitalier Régional Universitaire de Besançon

sfrancois@chu-besancon.fr0033381218988

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026